Fibrocell Plunges 40% After Second Stage azficel-T Trial Fails To Meet Primary Endpoints
June 08, 2016 at 10:35 AM EDT
Fibrocell Science, Inc. (NASDAQ: FCSC) revealed that the primary endpoints were not met in its second stage clinical trial of ...